Unprecedented demand for GLP-1 receptor agonists has strained worldwide pharmaceutical supply chains, forcing manufacturers to allocate unprecedented capital toward expanding sterile fill-finish infrastructure.
Production Bottlenecks
The primary constraint in meeting global market demand remains the specialized cold-chain and sterile injection pen assembly processes, rather than active pharmaceutical ingredient (API) synthesis.
Economic Ripple Effects
Insurance providers and national healthcare services are implementing stricter authorization criteria to control expenditure, directly influencing prescription volumes and corporate earnings projections.